Regulation
SkylineDX’s predictive melanoma test secures FDA breakthrough designation
SkylineDX received FDA breakthrough device designation for a predictive test that stratifies cutaneous melanoma patients into metastatic risk categories to guide treatment decisions. The test uses patient data to assess progression risk and inform clinical management protocols.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network